Background Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its broad
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …

Objectives: To evaluate the safety and efficacy of 5-year, long-term tocilizumab monotherapy
for patients with rheumatoid arthritis. Methods: In an open-label, long-term extension trial …

Tocilizumab, a humanized monoclonal antibody to the interleukin 6 (IL-6) receptor, was
approved for use as rheumatoid arthritis (RA) therapy in Japan in 2008, but its efficacy and …

Background Roughly a third of patients with rheumatoid arthritis treated with biological
treatments receive them as monotherapy. Tocilizumab—an inhibitor of interleukin 6 receptor …

Objectives: The phase III RADIATE study examined the efficacy and safety of tocilizumab, an
anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to …

Objectives To confirm the effectiveness and safety of the interleukin 6-receptor antagonist
tocilizumab in patients with rheumatoid arthritis (RA) in a setting close to real-life medical …

The dawn of the biologic era has been an exciting period for clinical research and patient
care in rheumatoid arthritis (RA). Targeted biologic therapies have changed the outcome of …

Because of the pathological role of IL-6 in rheumatoid arthritis (RA), tocilizumab (TCZ), a
humanized anti-IL-6 receptor monoclonal antibody, was expected to improve inflammation …

Objective To establish the safety and efficacy of repeat infusions of tocilizumab (previously
known as MRA), a humanized anti–interleukin‐6 (IL‐6) receptor antibody, alone and in …

Background: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of
IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. Objective: To evaluate through …